Drug profile

The FDA adverse-event record for Mycophenolate Mofetil

19 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Mycophenolate Mofetil. See the species affected, top reactions, and outcomes below.

19
adverse-event reports
36.8%
death-coded share
Dog
most-reported species
6
Leucocytosis NOS - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
19
Total Reports
7
Deaths Reported
36.8%
Death Rate

Active Ingredients

Mycophenolate Mofetil

Administration Routes

UnknownOral

Species Affected

Dog 17
Human 2

Most Affected Breeds

Retriever - Labrador 5
Unknown 2
Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) 2
Boxer (German Boxer) 1
Dog (unknown) 1
Corgi (unspecified) 1
Pug 1
Dachshund - Standard Smooth-haired 1
Terrier (unspecified) 1
Crossbred Canine/dog 1

Most Reported Reactions

Leucocytosis NOS 6
Vomiting 6
Immune mediated haemolytic anaemia 6
Lethargy (see also Central nervous system depression in 'Neurological') 5
Diarrhoea 5
Thrombocytopenia 4
Neutrophilia 4
Death by euthanasia 4
Not eating 4
Anorexia 4
Lethargy (see also Central nervous system depression in Neurological) 4
Death 3

Outcome Breakdown

Ongoing
8 (42.1%)
Euthanized
4 (21.1%)
Died
3 (15.8%)
Recovered/Normal
2 (10.5%)
Outcome Unknown
2 (10.5%)

Mycophenolate Mofetil Adverse Event Insights

19 reports name Mycophenolate Mofetil; 7 recorded a death outcome (36.8% of reported events, not a population-level mortality rate). Active ingredient: Mycophenolate Mofetil. Administration routes: Unknown, Oral.

By species: Dog (17 reports), Human (2 reports). By breed: Retriever - Labrador (5), Unknown (2), Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) (2).

Leading clinical signs: Leucocytosis NOS (6), Vomiting (6), Immune mediated haemolytic anaemia (6), Lethargy (see also Central nervous system depression in 'Neurological') (5). Outcome, 19 coded reports: Ongoing leads at 42.1%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.